NCT06022055Recruiting
Multimodal Study of the Human Brain Epilepsy Tissue
Source: ClinicalTrials.gov · Last updated 16 Jul 2026
Brief summary (registry, in English)
The TIPI2 study is a blood and tissue collection protocol to create an annotated biorepository to support research in drug-resistant epilepsy. The aim of the study will be to identify new pathophysiological pathways. For this purpose, the investigators will investigate with a multimodal approach blood and brain samples from patients undergoing a surgery for focal drug-resistant epilepsy. The adult patients will be enrolled either during the pre-surgical evaluation or right before the surgery.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- First submitted
- 22 May 2023
- Start date
- 29 Feb 2024
- Primary completion date
- 28 Feb 2037
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Diseases
- Epilepsy
- NCT number
- NCT06022055
What you commit to
- Study type: Interventional
- Planned participants: 300
- From 29 Feb 2024 to the primary completion date, 28 Feb 2037
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- None
Who the study is looking for
- 18 yo or above
- patients with a focal drug-resistant epilepsy
- patients hospitalized for a pre-surgical evaluation or for an epilepsy surgery
- consent obtained from the patient, or legally authorized representative
- affiliated to a social security system
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Neurology, Epilepsy Unit, Pitié-Salpêtrière Hospital Coordinator of this site? Confirm its status | Paris | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.